{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:29:43Z","timestamp":1751023783332},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1797-3","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T03:26:36Z","timestamp":1478143596000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland"],"prefix":"10.1186","volume":"16","author":[{"given":"Fardod","family":"O\u2019Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustom","family":"Manecksha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me P.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"1797_CR1","first-page":"625170","volume":"2012","author":"RH-P Dhillon","year":"2012","unstructured":"Dhillon RH-P, Clark J. ESBLs: a clear and present danger? Crit Care Res Pract. 2012;2012:625170.","journal-title":"Crit Care Res Pract"},{"key":"1797_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dki239","volume":"56","author":"DM Livermore","year":"2005","unstructured":"Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother. 2005;56:451\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-12-116","volume":"12","author":"J Fennell","year":"2012","unstructured":"Fennell J, et al. Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC Infect Dis. 2012;12:116.","journal-title":"BMC Infect Dis"},{"key":"1797_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2334-13-19","volume":"13","author":"I Linhares","year":"2013","unstructured":"Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000\u20132009). BMC Infect Dis. 2013;13:19.","journal-title":"BMC Infect Dis"},{"key":"1797_CR5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/JCM.00219-10","volume":"48","author":"KS Thomson","year":"2010","unstructured":"Thomson KS. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues. J Clin Microbiol. 2010;48:1019\u201325.","journal-title":"J Clin Microbiol"},{"key":"1797_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","volume":"86","author":"SS Kanj","year":"2011","unstructured":"Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc. 2011;86:250\u20139.","journal-title":"Mayo Clin Proc"},{"key":"1797_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.12659\/MSM.883898","volume":"19","author":"M Pobiega","year":"2013","unstructured":"Pobiega M, et al. Molecular characterization and drug resistance of Escherichia coli strains isolated from urine from long-term care facility residents in Cracow, Poland. Med Sci Monit. 2013;19:317\u201326.","journal-title":"Med Sci Monit"},{"key":"1797_CR8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.bjid.2012.05.001","volume":"16","author":"P Martinez","year":"2012","unstructured":"Martinez P, Garz\u00f3n D, Mattar S. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia. Braz J Infect Dis. 2012;16:420\u20135.","journal-title":"Braz J Infect Dis"},{"key":"1797_CR9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1469-0691.2009.02941.x","volume":"16","author":"OK Azap","year":"2010","unstructured":"Azap OK, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147\u201351.","journal-title":"Clin Microbiol Infect"},{"key":"1797_CR10","first-page":"E060831.1","volume":"11","author":"H Pelly","year":"2006","unstructured":"Pelly H, et al. Outbreak of extended spectrum beta-lactamase producing E. coli in a nursing home in Ireland, May 2006. Euro Surveill. 2006;11:E060831.1.","journal-title":"Euro Surveill"},{"key":"1797_CR11","doi-asserted-by":"crossref","unstructured":"Ludden C, et al. Colonisation with ESBL-producing and carbapenemase-producing Enterobacteriaceae, vancomycin-resistant enterococci, and meticillin-resistant Staphylococcus aureus in a long-term care facility over one year. BMC Infect Dis. 2015;15:168.","DOI":"10.1186\/s12879-015-0880-5"},{"key":"1797_CR12","unstructured":"EARS-Net Report, Quarter 1-4 2015. Health Protection Surveillance Centre 2016. http:\/\/www.hpsc.ie\/A-Z\/MicrobiologyAntimicrobialResistance\/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS\/EARSSSurveillanceReports\/2015Reports\/File,15214,en . Accessed June 2016."},{"key":"1797_CR13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ajic.2012.09.016","volume":"41","author":"B Al-Assil","year":"2013","unstructured":"Al-Assil B, Mahfoud M, Hamzeh AR. Resistance trends and risk factors of extended spectrum \u03b2-lactamases in Escherichia coli infections in Aleppo, Syria. Am J Infect Control. 2013;41:597\u2013600.","journal-title":"Am J Infect Control"},{"key":"1797_CR14","first-page":"645","volume":"43","author":"T Ho\u015fbul","year":"2009","unstructured":"Ho\u015fbul T, et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul. 2009;43:645\u20139.","journal-title":"Mikrobiyol Bul"},{"issue":"Suppl 3","key":"1797_CR15","first-page":"iii25","volume":"65","author":"A Pallett","year":"2010","unstructured":"Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65(Suppl 3):iii25\u201333.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR16","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.01760-09","volume":"54","author":"S Auer","year":"2010","unstructured":"Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:4006\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dki451","volume":"57","author":"K Thomas","year":"2006","unstructured":"Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother. 2006;57:367\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"1797_CR18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","volume":"22","author":"W Graninger","year":"2003","unstructured":"Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003;22(Suppl 2):73\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"1797_CR19","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","volume":"55","author":"KM Papp-Wallace","year":"2011","unstructured":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55:4943\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumi. Antimicrob Agents Chemother. 2010;54:602\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jac\/11.5.427","volume":"11","author":"MJ Hall","year":"1983","unstructured":"Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983;11:427\u201333.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR22","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.40.8.1914","volume":"40","author":"RL White","year":"1996","unstructured":"White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40:1914\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR23","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1128\/AAC.42.7.1574","volume":"42","author":"J Prieto","year":"1998","unstructured":"Prieto J, et al. In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Antimicrob Agents Chemother. 1998;42:1574\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.medmal.2011.07.005","volume":"42","author":"Y Neuzillet","year":"2012","unstructured":"Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy. Med Mal Infect. 2012;42:66\u201375.","journal-title":"Med Mal Infect"},{"key":"1797_CR25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1464-410X.2011.10528.x","volume":"109","author":"IM Cullen","year":"2012","unstructured":"Cullen IM, et al. The changing pattern of antimicrobial resistance within 42,033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999\u20132009. BJU Int. 2012;109:1198\u2013206.","journal-title":"BJU Int"},{"key":"1797_CR26","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.01523-12","volume":"57","author":"FNJ Frakking","year":"2013","unstructured":"Frakking FNJ, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-\u03b2-lactamase-producing bacteria. Antimicrob Agents Chemother. 2013;57:3092\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1797_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2013.05.006","author":"N-C Fan","year":"2013","unstructured":"Fan N-C, et al. Rise of community-onset urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2013. doi: 10.1016\/j.jmii.2013.05.006 .","journal-title":"J Microbiol Immunol Infect"},{"key":"1797_CR28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3143\/geriatrics.48.530","volume":"48","author":"A Yamamoto","year":"2011","unstructured":"Yamamoto A. Extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli is frequently detected as a pathogen of urinary tract infection in nursing home residents. Nihon Ronen Igakkai Zasshi. 2011;48:530\u20138.","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"1797_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkt368","volume":"69","author":"S Dewar","year":"2014","unstructured":"Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother. 2014;69:303\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.1992.tb04092.x","volume":"33","author":"A Heikkil\u00e4","year":"1992","unstructured":"Heikkil\u00e4 A, Pyykk\u00f6 K, Erkkola R, Iisalo E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. Br J Clin Pharmacol. 1992;33:629\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"1797_CR31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2125.1976.tb04886.x","volume":"3","author":"J Andrews","year":"1976","unstructured":"Andrews J, Kendall MJ, Mitchard M. Factors influencing the absorption and disposition of mecillinam and pivmecillinam in man. Br J Clin Pharmacol. 1976;3:627\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"1797_CR32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","volume":"10","author":"KK Kumarasamy","year":"2010","unstructured":"Kumarasamy KK, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597\u2013602.","journal-title":"Lancet Infect Dis"},{"key":"1797_CR33","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1093\/jac\/dks215","volume":"67","author":"N Lampri","year":"2012","unstructured":"Lampri N, et al. Mecillinam\/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2012;67:2424\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR34","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/jac\/dkt159","volume":"68","author":"HO Poulsen","year":"2013","unstructured":"Poulsen HO, Johansson A, Granholm S, Kahlmeter G, Sundqvist M. High genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli indicates low propensity for clonal spread. J Antimicrob Chemother. 2013;68:1974\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"1797_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/46.suppl_1.9","volume":"46","author":"W Sougakoff","year":"2000","unstructured":"Sougakoff W, Jarlier V. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother. 2000;46(Suppl 1):9\u201314. discussion 63\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"1797_CR36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3855\/jidc.361","volume":"1","author":"S Kariuki","year":"2007","unstructured":"Kariuki S, et al. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams. J Infect Dev Ctries. 2007;1:257\u201362.","journal-title":"J Infect Dev Ctries"},{"key":"1797_CR37","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/JCM.00999-13","volume":"51","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2013","unstructured":"Rodr\u00edguez-Ba\u00f1o J, et al. Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol. 2013;51:2414\u20137.","journal-title":"J Clin Microbiol"},{"key":"1797_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/cir323","volume":"53","author":"S Miyakis","year":"2011","unstructured":"Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis. 2011;53:177\u201384.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1797-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T07:11:07Z","timestamp":1568531467000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1797-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1797-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]},"article-number":"620"}}